DROR · XBRL financial data

Dror Ortho-Design financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DROR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	247	408*	374	389	451	326*	240	324	151	101*	118	151
General and administrative	308	396*	386	333	308	411*	314	391	318	344*	379	345
Total operating expenses	555	3,057*	1,296	1,497	1,302	1,129*	576	732	470	445*	497	496
Operating income (loss)	(555)	(3,057)*	(1,296)	(1,497)	(1,302)	(1,129)*	(576)	(732)	(470)	(445)*	(497)	(496)
Other income (expense)	2	74*	(12)	(10)	(5)	(5)*	0	(15)	(16)	(10)*	2	(11)
Net income (loss)	(554)	(2,263)*	(1,308)	(1,507)	(1,827)	(1,134)*	(576)	(759)	(654)	(556)*	(639)	(625)
Earnings per share, basic USD per share	0.00	—	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00*	0.00	0.00
Earnings per share, diluted USD per share	0.00	—	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00*	0.00	0.00
Weighted average shares, basic thousands of shares	309,568	—	495,455	495,455	738,291	—	956,997	956,997	956,997	956,997*	976,098	976,997
Weighted average shares, diluted thousands of shares	309,568	—	495,455	495,455	738,291	—	956,997	956,997	956,997	956,997*	976,098	976,997

Fiscal quarters (DROR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	4,016	3,348	2,550	1,834	1,143	549	350	64	240	229	24	94
Prepaid and other current assets	147	114	105	60	99	89	71	46	10	10	211	255
Total current assets	4,162	3,462	2,655	1,895	1,242	639	420	111	251	239	235	348
Property and equipment, net	2	2	19	27	25	24	23	22	20	20	19	18
Total assets	4,165	3,464	2,674	1,921	1,267	663	443	133	271	259	254	366
Accounts payable	6	107	6	94	85	215	248	406	447	114	102	103
Total current liabilities	981	297	278	258	888	907	1,231	1,639	2,420	2,957	3,379	4,100
Total liabilities	981	302	283	263	893	1,031	1,364	1,797	2,589	3,133	3,566	4,303
Accumulated deficit	(11,468)	(13,731)	(15,039)	(16,546)	(18,373)	(19,507)	(20,083)	(20,842)	(21,496)	(22,052)	(22,690)	(23,315)
Total stockholders' equity	3,184	3,162	2,391	1,658	374	(368)	(921)	(1,664)	(2,318)	(2,874)	(3,312)	(3,938)
Total liabilities and equity	4,165	3,464	2,674	1,921	1,267	663	443	133	271	259	254	366
Common shares outstanding (cover page) thousands of shares	495,455	495,455	495,455	495,455	956,997	956,997	956,997	956,997	956,997	976,997	976,997	976,997

Fiscal quarters (DROR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(554)	(2,263)*	(1,308)	(1,507)	(1,827)	(1,134)*	(576)	(759)	(654)	(556)*	(639)	(625)
Stock-based compensation	3	2,241*	537	774	543	391*	23	16	0*	0*	—	—
Net cash from operating activities	(1,689)*	(626)*	(781)	(706)*	(691)*	(563)*	(500)	(485)*	(424)*	(649)*	(404)	(305)*
Purchases of property and equipment	—	—	17	9*	0*	0*	—	—	—	year only	—	—
Net cash from investing activities	—	0*	(17)	(9)*	0*	0*	—	—	—	year only	—	—
Net cash from financing activities	4,675*	(42)*	—	—	—	—	300	200*	600*	650*	200	375*
Net change in cash	3,982*	(668)*	(798)	(716)*	(691)*	(594)*	(200)	(285)*	176*	(12)*	(205)	70*

SIC 3843 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3843 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Dror Ortho-Design	94	not reported	(305)*	977.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Neuraxis	8,322	1,929	(1,030)*	12.6M	—	Q2 FY26 10-QJun 30, 2026
Allurion Technologies	5,056	2,947	(3,221)	15.0M	1.6 quarters	Q1 FY26 10-QMar 31, 2026
Positron	357	112	(1,050)*	32.8M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.